Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · March 14, 2023

[18F]FDG and [18F]FES PET/CT Imaging for Predicting Response to Rintodestrant in Patients With Metastatic ER+ Breast Cancer

Clinical Cancer Research


Additional Info

Clinical Cancer Research
[18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant
Clin. Cancer Res 2023 Feb 03;[EPub Ahead of Print], R Iqbal, M Yaqub, HO Bektas, DE Oprea-Lager, EGE de Vries, AWJM Glaudemans, P Aftimos, G Gebhart, AP Beelen, RC Schuit, AD Windhorst, R Boellaard, CW Menke-van der Houven van Oordt

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading